Indivior suffers a major downfall due to its loss in the patent case

PUBLISHED BY
Carrie Ann



TAGS:


4 years ago




There are two factors in life the leniency of which can cause major physical as well as mental issues.  One is getting the right diagnosis by the doctor and the other is an intake of the right medicines. If any of these go wrong, you may have to strive hard to survive. But if they are done right, then it can lead you to a healthier life. After all, if you don’t have a healthy life than money and success are unimportant. This is why any kind of negative publicity can adversely affect the progress rate of any pharmaceutical company. This is what happened with Indivior as well.

Indivior is a pharmaceutical company based in London which was founded in the year of 1994. The company mainly specializes in producing medicines that can help you get rid of an addiction. This is very tricky business as a consumer may get the hang of using these medicines as an alternative to addiction. This is why pharmaceutical manufacturers have to be precise with their chemical formulas. Owing to this kind of importance, Indivior was proud of its expertise. Turns out that its field of expertise wasn’t unique after all. This knowledge came to the light after a recent ruling by the U.S. court. Also, it led to the decline of the company in terms of its share prices.

Indivior

Indivior is a pharmaceutical company based in London which was founded in the year of 1994.

More about Indivior’s patent case

Friday morning witness the drop of Indivior’s stock prices by almost 40 percent. This sudden downfall took place as a result of the U.S. court ruling not turning out in the company’s favor. The company had challenged its rivals in the U.S. court that they had infringed upon its patent of a particular drug. The company majorly attains its income through Suboxone, which is a heroin addiction treatment. As it generates most of its finance from the sale of this drug, it wanted to make sure that no other company sold the same. But its plan significantly backfired.

As Indivior lost the case, its competitive rivals can legally produce a drug similar to Suboxone. This can cause tremendous loss to the company as Suboxone has 61 percent of market share in the U.S. itself. The sale of this drug adds up to 80 percent of the company’s revenue. CEO of Indivior, Shaun Thaxter stated that the company is extremely disappointed with the legal ruling. There is no definite idea about the loss it will cause but its adverse effects are already visible.

Carrie Ann
Carrie Ann is Editor-in-Chief at Industry Leaders Magazine, based in Las Vegas. Carrie covers technology, trends, marketing, brands, productivity, and leadership. When she isn’t writing she prefers reading. She loves reading books and articles on business, economics, corporate law, luxury products, artificial intelligence, and latest technology. She’s keen on political discussions and shares an undying passion for gadgets. Follow Carrie Ann on Twitter, Facebook

Recent Posts

Nokia to launch T20 tablet with 10.36 inch display

Nokia to launch T20 tablet with 10.36 inch display

The Nokia T20 will sport a 10.36-inch display and will have 4 GB RAM along with 64 gigs of native storage.
2 days ago
Ford sees surprise Q2 profit despite chip shortage and manufacturing hassles

Ford sees surprise Q2 profit despite chip shortage and manufacturing hassles

“The business is ‘spring loaded’ for a rebound when semiconductor supplies stabilize and more closely match demand.”
2 days ago
Audi A6 E-tron Production Launch in 2023

Audi A6 E-tron Production Launch in 2023

Audi has confirmed that there will be multiple variants of the etron, including “basic versions optimized for minimum consumption and maximum range.
3 days ago
Royal Dutch Shell buyback lifts investor sentiment

Royal Dutch Shell buyback lifts investor sentiment

Royal Dutch Shell commences share buybacks before the end of this year while reducing its first quarter dividend to 16 cents per share, a 66% cut.
3 days ago
Citizens Financial to acquire Investors Bancorp in $3.5 billion NYC push

Citizens Financial to acquire Investors Bancorp in $3.5 billion NYC push

Citizens Financial Group, Inc. and Investors Bancorp announced today that they have entered into a definitive agreement and plan of merger in a cash-and-stock deal worth $3.5 billi
3 days ago
Apple Q3 Earnings Break Records Again!

Apple Q3 Earnings Break Records Again!

Apple Q3 earnings prove the Cupertino giant remains unaffected by the Covid-19 pandemic as sales rise across all product lines.
4 days ago